MXPA05006989A - Derivados de diamina. - Google Patents

Derivados de diamina.

Info

Publication number
MXPA05006989A
MXPA05006989A MXPA05006989A MXPA05006989A MXPA05006989A MX PA05006989 A MXPA05006989 A MX PA05006989A MX PA05006989 A MXPA05006989 A MX PA05006989A MX PA05006989 A MXPA05006989 A MX PA05006989A MX PA05006989 A MXPA05006989 A MX PA05006989A
Authority
MX
Mexico
Prior art keywords
thrombosis
represent
syndrome
infarction
blood
Prior art date
Application number
MXPA05006989A
Other languages
English (en)
Inventor
Makoto Ono
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32684223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05006989(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of MXPA05006989A publication Critical patent/MXPA05006989A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto representado por la siguiente formula general (l): (ver formula (l)), Q1-Q2-T0N(R1)-Q3N(R2)-T1Q4(1) en donde R1 y R2 representa cada uno hidrogeno, etc.; Q1 representa opcionalmente hidrocarbilo ciclico de 5 a 6 elementos saturado o insaturado, etc.; Q2 representa un solo enlace, etc.; Q3 representa un grupo de la siguiente formula: (en donde Q5 representa alquileno de C1-8 etc.; y T0 y T1 representan cada uno carbonilo, etc.; su sal, solvatos de los mismos o N- oxidos de los mismos; estos compuestos son utiles como preventivos y/o remedios para infarto cerebral, embolia cerebral, infarto al miocardio, angina, infarto pulmonar, embolia pulmonar, enfermedad de Burger, trombosis venosa profunda, sindrome de coagulacion intravascular diseminada, trombosis despues del reemplazo de valvula/articulacion artificial, trombosis y reoclusion despues de reconstruir la circulacion sanguinea, sindrome de respuesta inflamatoria sistemica (SIRS), sindrome de disfuncion multiorganica (MODS), trombosis en circulacion extracorporea y coagulacion sanguinea en recoleccion sanguinea.
MXPA05006989A 2002-12-25 2003-12-25 Derivados de diamina. MXPA05006989A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002373787 2002-12-25
JP2003379163 2003-11-07
PCT/JP2003/016783 WO2004058715A1 (ja) 2002-12-25 2003-12-25 ジアミン誘導体

Publications (1)

Publication Number Publication Date
MXPA05006989A true MXPA05006989A (es) 2005-09-22

Family

ID=32684223

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006989A MXPA05006989A (es) 2002-12-25 2003-12-25 Derivados de diamina.

Country Status (14)

Country Link
US (3) US7576135B2 (es)
EP (1) EP1577301B1 (es)
JP (2) JP4109288B2 (es)
KR (1) KR20050110612A (es)
AU (1) AU2003292828B9 (es)
CA (1) CA2511493A1 (es)
ES (1) ES2393996T3 (es)
HK (1) HK1086006A1 (es)
IL (1) IL169349A0 (es)
MX (1) MXPA05006989A (es)
PL (1) PL377550A1 (es)
RU (1) RU2333203C2 (es)
TW (1) TW200500366A (es)
WO (1) WO2004058715A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI288745B (en) * 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) * 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
JP4630267B2 (ja) * 2002-12-25 2011-02-09 第一三共株式会社 ジアミン誘導体
CA2511493A1 (en) * 2002-12-25 2004-07-15 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US7205318B2 (en) * 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
ES2679744T3 (es) * 2003-11-12 2018-08-30 Daiichi Sankyo Company, Limited Procedimiento para producir derivados de tiazol
AU2005238386A1 (en) 2004-04-30 2005-11-10 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof as an MMP-13 inhibitor
EP1758580A4 (en) 2004-06-24 2008-01-16 Incyte Corp N-SUBSTITUTED PIPERIDINE AND ITS USE AS A MEDICAMENT
MX2007001540A (es) * 2004-08-10 2007-04-23 Incyte Corp Compuestos amido y sus usos como farmaceuticos.
IT1362675B (it) * 2005-03-15 2009-06-25 Menarini Internat Operations Luxembourg Sa N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
EP1864982B1 (en) 2005-03-31 2012-10-24 Daiichi Sankyo Company, Limited Triamine derivative
DE102005032209A1 (de) * 2005-07-09 2007-01-18 Lanxess Deutschland Gmbh 1-Cycloalkyl-5-Iodtetrazole
US20070032473A1 (en) * 2005-07-19 2007-02-08 Kai Gerlach Substituted amides and their use as medicaments
ES2569398T3 (es) 2005-09-16 2016-05-10 Daiichi Sankyo Company, Limited Derivado de diamina ópticamente activo y proceso para producir el mismo
KR20080067697A (ko) * 2005-11-11 2008-07-21 에프. 호프만-라 로슈 아게 응고 인자 ｘａ의 억제제로서 카보사이클릭 융합된사이클릭 아민
BRPI0618610A2 (pt) * 2005-11-16 2011-09-06 Hoffmann La Roche derivados de pirrolidina como inibidores de fator xa de coagulação
DE102005062990A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln
EP2062878A4 (en) 2006-08-30 2010-09-08 Shionogi & Co HYDRAZINE AMIDE DERIVATIVE
CN104324015B (zh) 2007-03-29 2018-08-28 第一三共株式会社 药物组合物
WO2010058751A1 (ja) * 2008-11-18 2010-05-27 第一三共株式会社 [１,３,４]オキサジアゾール化合物の薬理上許容される塩又はその水和物
EP2368870A1 (en) 2008-12-12 2011-09-28 Daiichi Sankyo Company, Limited Process for producing optically active carboxylic acid
RU2464271C1 (ru) 2008-12-17 2012-10-20 Дайити Санкио Компани, Лимитед Способ получения производного диамина
CN102325528A (zh) 2008-12-19 2012-01-18 第一三共株式会社 活化凝血因子X（FXa）抑制剂
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd INHIBITOR OF AN ACTIVE FACTOR OF BLOOD COAGULATION
CN102348688B (zh) 2009-03-10 2014-07-09 第一三共株式会社 用于制备二胺衍生物的方法
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
WO2010147169A1 (ja) 2009-06-18 2010-12-23 第一三共株式会社 溶出性の改善された医薬組成物
TWI500623B (zh) 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
US8541430B2 (en) * 2009-11-27 2013-09-24 Torrent Pharmaceuticals Limited Fused thiazolo and oxazolo pyrimidinones
EP2540318B1 (en) * 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
WO2011102506A1 (ja) 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
EP2540317A4 (en) * 2010-02-22 2014-04-16 Daiichi Sankyo Co Ltd SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION
BR112012023654B1 (pt) 2010-03-19 2022-04-12 Daiichi Sankyo Company, Limited Método para produzir grânulos contendo agente anticoagulante e método para produzir uma composição farmacêutica contendo o dito agente
WO2011115066A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
MX2012012502A (es) * 2010-04-27 2013-01-18 Hutchison Medipharma Ltd Compuestos pirimidinil indol.
HUE031961T2 (en) 2010-07-02 2017-09-28 Daiichi Sankyo Co Ltd A method for preparing an optically active salt of diamine derivative
KR101848952B1 (ko) 2010-08-04 2018-04-13 다이이찌 산쿄 가부시키가이샤 니트록시드 라디칼 화합물을 반응 촉매로 하는 신규 샌드마이어형 반응 성적체의 제조법
KR101940840B1 (ko) 2011-08-10 2019-01-21 다이이찌 산쿄 가부시키가이샤 디아민 유도체 함유 의약 조성물
EP2893928B1 (en) 2012-09-03 2018-10-24 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
TWI602803B (zh) 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
KR20150138214A (ko) 2013-03-29 2015-12-09 다이이찌 산쿄 가부시키가이샤 (1s,4s,5s)-4-브로모-6-옥사비시클로[3.2.1]옥탄-7-온의 제조 방법
CN106459087B (zh) * 2014-02-18 2019-04-09 第一三共株式会社 活化的凝血因子X (FXa)抑制剂的制备方法
KR20180022125A (ko) * 2016-08-23 2018-03-06 동화약품주식회사 디아민 유도체의 산부가염 및 이의 제조 방법
KR102333564B1 (ko) 2019-11-28 2021-12-01 동방에프티엘(주) 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로
WO2022129535A1 (en) 2020-12-18 2022-06-23 Krka, D.D., Novo Mesto Edoxaban formulation containing no sugar alcohols

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354120A (en) * 1964-02-26 1967-11-21 Monsanto Co Polyamides prepared from 5, 5'-diaminoindigo
JP2875930B2 (ja) * 1992-12-02 1999-03-31 富士写真フイルム株式会社 旋光フイルムおよびそれを用いた液晶表示装置
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
KR100323274B1 (ko) * 1993-10-19 2002-12-16 스미또모 세이야꾸 가부시키가이샤 2,3-디아미노프로피온산유도체
US5525042A (en) * 1993-11-08 1996-06-11 Clearline Systems, Inc. Liquid pump with compressed gas motive fluid
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
DE19536783A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope
US5852045A (en) * 1995-10-19 1998-12-22 Merck & Co., Inc. Fibrinogen receptor antagonists
US5668159A (en) * 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
UA56197C2 (uk) * 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
ATE334975T1 (de) * 1997-05-30 2006-08-15 Takeda Pharmaceutical Sulfonamidderivate, ihre herstellung und verwendung
ES2255733T3 (es) 1997-09-30 2006-07-01 Daiichi Pharmaceutical Co., Ltd. Derivados sulfonilo.
US6130349A (en) 1997-12-19 2000-10-10 The Board Of Trustees Of The Leland Stanford Junior University Catalytic compositions and methods for asymmetric allylic alkylation
DE19814801A1 (de) * 1998-04-02 1999-10-07 Basf Ag Verfahren zur Herstellung von 1,3,4-trisubstituierten 1,2,4-Triazoliumsalzen
TW434207B (en) * 1998-07-24 2001-05-16 Everlight Chem Ind Corp Chiral ligand and method for preparing cyanohydrins from aldehydes
EP1104754A1 (en) 1998-08-11 2001-06-06 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
GB9909592D0 (en) * 1999-04-26 1999-06-23 Chirotech Technology Ltd Process for the preparation of calanolide precursors
US6797720B2 (en) * 1999-12-03 2004-09-28 Ono Pharmaceutical Co., Ltd. 1,3,4-oxadiazoline derivative and an agent comprising its derivative as active ingredient
JP4754753B2 (ja) * 2000-02-10 2011-08-24 ザ ペン ステイト リサーチ ファンデーション キラルフェロセンホスフィン及び不斉触媒反応におけるその使用
TWI288745B (en) * 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) * 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
IL159438A0 (en) * 2001-06-20 2004-06-01 Daiichi Seiyaku Co Diamine derivatives
ATE556066T1 (de) * 2001-08-09 2012-05-15 Daiichi Sankyo Co Ltd Diaminderivate
UA78232C2 (uk) * 2001-09-21 2007-03-15 Брістол-Майерс Сквібб Компані Лактамвмісні сполуки та їх похідні як інгібітори фактора ха
JP4266092B2 (ja) * 2001-10-09 2009-05-20 第一三共株式会社 ジアミン誘導体
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
GB0205170D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
EP1505966A4 (en) * 2002-05-10 2006-08-30 Bristol Myers Squibb Co 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA HEMMER
SI2527315T1 (sl) 2002-05-31 2014-06-30 Proteotech Inc., Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
WO2004058728A1 (ja) * 2002-12-24 2004-07-15 Daiichi Pharmaceutical Co., Ltd. 新規なエチレンジアミン誘導体
CA2511493A1 (en) 2002-12-25 2004-07-15 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives

Also Published As

Publication number Publication date
AU2003292828B9 (en) 2009-10-01
HK1086006A1 (en) 2006-09-08
CA2511493A1 (en) 2004-07-15
AU2003292828B2 (en) 2009-09-10
AU2003292828A1 (en) 2004-07-22
US20090281074A1 (en) 2009-11-12
EP1577301B1 (en) 2012-09-12
WO2004058715A1 (ja) 2004-07-15
IL169349A0 (en) 2007-07-04
TW200500366A (en) 2005-01-01
ES2393996T3 (es) 2013-01-04
RU2005123394A (ru) 2006-05-27
US7576135B2 (en) 2009-08-18
JPWO2004058715A1 (ja) 2006-04-27
US20060252837A1 (en) 2006-11-09
JP4109288B2 (ja) 2008-07-02
JP4809850B2 (ja) 2011-11-09
PL377550A1 (pl) 2006-02-06
US20100099660A1 (en) 2010-04-22
EP1577301A1 (en) 2005-09-21
RU2333203C2 (ru) 2008-09-10
KR20050110612A (ko) 2005-11-23
EP1577301A4 (en) 2009-11-11
JP2008138011A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
MXPA05006989A (es) Derivados de diamina.
MXPA04001272A (es) Derivados de diamina.
MXPA03011951A (es) Derivados de diamina.
MY153231A (en) Diamine derivatives
EA200200194A1 (ru) Антагонисты хемокинного рецептора и способы их применения
EP0370498A3 (en) Trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds and pharmaceutical use thereof
ATE291013T1 (de) Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten
LU90562I2 (fr) Acides imidazoalc-noiques
EP0403158A3 (en) Imidazolyl-alkenoic acids
TW200510369A (en) Novel ethylenediamine derivatives
YU205590A (sh) Amidi imidazo (4,5-b)hinolinoloksi alkanovih kiselina sa poboljšanom rastvorljivošću u vodi i postupak za dobijanje
CA2383298A1 (fr) Nouveaux derives d'.alpha.-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
WO2002018383A3 (en) Aza heterocyclic derivatives and their therapeutic use
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
LV12634A (lv) Watersoluble azole antifungals
EA200200952A1 (ru) Производные циклогексиламина в качестве селективных антагонистов подтипов nmda-рецепторов
SE9703414D0 (sv) New compounds
EA200200348A1 (ru) Фармацевтические растворы левосимендана
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
ATE399011T1 (de) Substituierte diketopiperazine als oxytocin- antagonisten
DK1377164T3 (da) Erythropoietin forbedrer kemoterapi-induceret toksicitet in vivo
EA200201158A1 (ru) Бициклические циклогексиламины и их применение в качестве антагонистов nmda-рецепторов
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
EA200000693A1 (ru) Антагонисты хемокинного рецептора и способы их применения

Legal Events

Date Code Title Description
FG Grant or registration